Sustainability & Climate

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

Seven Colombian designers are captivating Paris Fashion Week, weaving ancestral craft and modern style into a strategic play for global economic recognition.

Phonak's new hearing aids won a top design award, blending advanced AI with discreet style to change how we see and hear with assistive technology.

Vermilion Energy boosts its dividend for the fifth straight year, a move backed by strong cash flow and a strategic focus on premium gas markets.

Nofar Energy's acquisition of a 45.9% stake in Ellomay Capital triggers a board overhaul and signals a new era of strategic consolidation in renewables.

The healthcare provider posted robust annual growth and cash flow, but a tough Q4 and a prudent 2026 forecast reveal deepening industry-wide pressures.

OmniAb reported declining revenue and a wider net loss for 2025, even as it launched its revolutionary OmniUltra platform and its partners' drugs advance.

MISTRAS Group reported record Adjusted EBITDA for 2025, signaling a successful shift to profitability over pure growth, and plans major tech investments.

The staffing firm saw revenue fall 22% and posted a $95M net loss in 2025, now pivoting to its tech platform and cost cuts for a comeback.

With a new CEO at the helm and market pressures mounting, Daktronics' upcoming Investor Day is a pivotal moment to unveil its strategy for profitable growth.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

JLC LIVE returns to Providence with new clinics, tool zones, and diversity initiatives to tackle construction's biggest challenges: labor, costs, and tech.

Yarbo's all-season yard robot hit $1M on Kickstarter in record time, signaling a major shift in how we manage our lawns, gardens, and driveways.

The Royal Ballet School is re-establishing its elite training in the North East, partnering with Dance City to nurture the next generation of dancers.

With AI and disruption reshaping business, a new summit urges tech execs to lead like CEOs. Discover the 'Iconic Leadership' model for the enterprise of 2030.